Every Form 4 that GERON CORP WT 25 (GERNW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GERNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GERNW filings page.
Geron Corp director Robert J. Spiegel was granted a stock option for 220,000 shares of common stock. The option has an exercise price of $1.26 per share and expires on May 19, 2036.
The option will vest and become exercisable for 100% of the shares on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, as long as Spiegel remains in continuous service with Geron through that date.
GERON CORP director Elizabeth G. O'Farrell received a grant of stock options covering 220,000 shares of common stock. The options have an exercise price of $1.26 per share and expire on May 19, 2036. They vest 100% on the earlier of the next annual stockholder meeting or the first anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds 220,000 options directly.
Geron Corp director Susan Molineaux received a compensation grant of stock options covering 220,000 shares of common stock at an exercise price of $1.26 per share. The option vests in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, contingent on her continuous service. Any unexercised portion expires on May 19, 2036. This is an equity award, not an open-market stock purchase or sale.
Geron Corp director John F. McDonald received a grant of 220,000 stock options to buy Geron common stock. The options have an exercise price of $1.26 per share and expire on May 19, 2036, providing long-term equity-based compensation.
According to the terms, the option will vest and become exercisable for all 220,000 underlying shares on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, as long as McDonald continues to serve the company through that date. There were 220,000 derivative securities held after this grant, and the filing shows no open-market buying or selling.
Geron Corp director Dawn Carter Bir received a new stock option grant. On 2026-05-20, she was awarded options to acquire 220,000 shares of Geron common stock at an exercise price of $1.2600 per share, with no cost for the grant itself.
The option covers 220,000 underlying common shares and expires on 2036-05-19. According to the terms, it will vest and become exercisable in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, provided she maintains continuous service with Geron through that date.
Geron Corp reported that EVP and Chief Legal Officer Timothy Williams received a grant of stock options. He was awarded options to buy 2,500,000 shares of Geron common stock at an exercise price of $1.73 per share, expiring on April 12, 2036.
According to the vesting terms, 312,500 shares underlying the option will vest on October 13, 2026, with the remaining shares vesting in equal installments over the following 42 months, assuming he continues serving the company on each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Spiegel Robert J. reported acquisition or exercise transactions in this Form 4 filing.
Geron Corp director Robert J. Spiegel received 5,243 shares of common stock as part of his board compensation. The shares were granted in lieu of cash for his quarterly board retainer and committee fees, using a reference price of $1.49 per share based on the March 31, 2026 closing price. Following this stock award, he directly holds 199,707 Geron common shares.
Geron Corp director Constantine Chinoporos received a grant of stock options, not an open-market share purchase. The award covers 270,000 options to buy Geron common stock at an exercise price of $1.57 per share and expires on March 24, 2036.
The options will vest in three equal annual installments starting on March 25, 2027, subject to his continuous service with the company through each vesting date. Following this grant, he holds 270,000 stock options directly according to the filing.
Geron Corporation director Patricia S. Andrews received a grant of 270,000 stock options to buy Geron common stock. The options have an exercise price of $1.57 per share and expire on March 24, 2036. They vest in three equal annual installments starting on March 25, 2027, contingent on her continued service. Following this grant, she holds 270,000 stock options directly.
Eid Joseph reported acquisition or exercise transactions in this Form 4 filing.
Geron Corporation reported that EVP, R&D and Chief Medical Officer Joseph Eid received a grant of stock options covering 2,220,000 shares. The options were awarded at a reported price of $0.00 per share and are held directly. The grant vests in 48 equal monthly installments starting on March 17, 2026, as long as he continues to provide service on each vesting date.
Geron Corporation executive Michelle Robertson, EVP and Chief Financial Officer, reported several equity transactions. On February 18, 2026, 27,500 restricted stock units vested and converted into the same number of common shares, with each RSU representing one share. On the same date, 9,855 common shares were sold at $1.94 per share solely to cover tax withholding obligations under a mandatory sell-to-cover policy, rather than as a discretionary sale. Separately, on February 17, 2026, she received a stock option grant for 1,660,000 shares, vesting in 48 equal monthly installments starting March 17, 2026, contingent on continued service.